狼疮性肾炎 中国就医指南

Lupus nephritis (LN) is a severe, immune-mediated kidney complication of systemic lupus erythematosus (SLE), characterized by inflammation and damage to the glomeruli, tubules, interstitium, and vasculature of the kidneys. It occurs when autoantibodies—particularly anti-double-stranded DNA (anti-dsDNA) and anti-nuclear antibodies—form immune complexes that deposit in renal tissues, triggering complement activation, leukocyte infiltration, and cytokine-driven inflammation. This cascade leads to progressive glomerular injury, proteinuria, hematuria, hypertension, and, if untreated, irreversible fibrosis and end-stage kidney disease. LN affects approximately 30–60% of SLE patients over their lifetime, with higher incidence among individuals diagnosed with SLE before age 40. Epidemiologically, LN disproportionately impacts women (female-to-male ratio ~9:1), particularly those of African, Hispanic, Asian, and Indigenous descent—populations exhibiting both higher SLE prevalence and more aggressive renal involvement. Key risk factors include genetic susceptibility (e.g., variants in IRF5, STAT4, HLA-DR2/DR3), early-onset SLE (<20 years), persistent high disease activity, serologic markers like low C3/C4 and elevated anti-dsDNA titers, and socioeconomic barriers to timely care. Beyond physical morbidity, LN significantly impairs quality of life: chronic fatigue, pain, cognitive dysfunction ('lupus fog'), anxiety and depression are common; treatment-related side effects—including corticosteroid-induced weight gain, osteoporosis, diabetes, and infection risk—further diminish functional capacity and psychosocial well-being. Patients often face work disability, reduced social participation, and caregiver dependency, especially during flares or dialysis-dependent stages. Early diagnosis via urine analysis (proteinuria >0.5 g/day, active sediment), serum creatinine, eGFR, and confirmatory renal biopsy (classified per ISN/RPS 2003 criteria) is critical. Without intervention, up to 10–30% of LN patients progress to end-stage kidney disease within 10 years. Modern management emphasizes immunosuppression tailored to histopathologic class (e.g., Class III/IV treated with mycophenolate mofetil or cyclophosphamide plus glucocorticoids; Class V with calcineurin inhibitors), alongside rigorous blood pressure control (target <120/80 mmHg), RAAS blockade, and lifestyle optimization. Emerging biologics—including belimumab (approved for active LN) and voclosporin (FDA-approved for active LN)—are reshaping therapeutic paradigms toward improved renal preservation and reduced steroid burden.

# 狼疮性肾炎治疗方案与费用明细（肾内科）

一、非手术/药物保守治疗（一线首选）

适用人群：活动性LN（Ⅲ～Ⅴ型）、eGFR ≥30 mL/min/1.73m²、无严重感染/禁忌证者

• •基础方案（糖皮质激素+免疫抑制剂）：

- 费用区间： - 药物费（首年）：¥8,000–¥25,000（国产MMF ¥3,500–¥6,000/年；进口MMF ¥12,000–¥20,000/年；IV-CYC疗程¥4,000–¥8,000） - 必查项目（基线+每3月监测）：尿常规、24h尿蛋白定量、血清肌酐/eGFR、抗dsDNA、补体C3/C4、肝肾功、血常规、HBV/HCV筛查 → ¥1,200–¥2,500/次

二、介入/核心治疗（难治性/快速进展者）

适用人群：激素抵抗、重度蛋白尿（>3.5g/d）、新月体＞50%（肾活检证实）

• •血浆置换联合免疫抑制（每周2–3次×2–4周）+ 大剂量甲泼尼龙冲击

- 术前检查（含肾穿刺活检）：¥3,800–¥5,200 - 血浆置换（单次）+ 免疫吸附耗材：¥2,600–¥4,000/次（4–6次总费用约¥10,000–¥22,000）

三、特殊复杂方案（耐药/终末期/并发症）

• •生物制剂（贝利尤单抗）：适用于传统治疗失败者，需医保谈判后自付约¥30,000–¥45,000/年
• •终末期LN（ESRD）：进入透析（HD/腹透）或肾移植评估，透析年均费用¥60,000–¥120,000（含医保报销后自付）

方案快速选择指南

• •预算有限/初治轻中度：选国产MMF+激素方案（年总支出¥12,000–¥18,000）
• •中高预算/高风险病理：优选血浆置换+MMF强化诱导（首年总费用¥25,000–¥45,000）
• •耐药/反复复发：启动贝利尤单抗（需专科评估+医保备案）